Study # S2302

A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Study Status:

Enrolling

Treatment Agent:

Pembrolizumab, Ramucirumab

Description

Short Title: PRAGMATICA

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. 

Resources and Links

National Clinical Trial Identified Number: NCT05633602

Information and next steps

Disease:

  • Recurrent Lung Non-Small Cell Carcinoma,
  • Stage IV Lung Cancer

Study Phase:

III

Physician Name:

Department:

Ask a Question